Sarcopenia is associated with prognosis in patients with esophageal squamous cell cancer after radiotherapy or chemoradiotherapy

Table 3 Univariate and multivariate analyses of PFS

Characteristic	Univariate			Multivariate
Characteristic	HR	95% CI	p value	HR	95% CI	p value
Age (≥ 65 vs. < 65)	1.126	0.847–1.496	0.414
Sex (male vs. female)	1.187	0.861–1.639	0.295
Smoking (yes vs. no)	1.093	0.827–1.446	0.531
Alcohol (yes vs. no)	1.401	1.056–1.859	0.019	1.539	1.144–2.070	0.016
BMI (≥ 24 vs. < 24)	0.746	0.550–1.011	0.059
NRI (≥ 100 vs. < 100)	0.614	0.429–0.879	0.008
Anemia (yes vs. no)	1.416	1.057–1.898	0.020	1.428	1.043–1.954	0.016
Albumin (≥ 40 vs. < 40)	0.589	0.421–0.822	0.002
Sarcopenia (yes vs. no)	1.546	1.086–2.202	0.016	1.509	1.052–2.164	0.018
TATI (> 83.0 vs. ≤ 83.0)	0.671	0.506–0.889	0.005
SATI (> 27.8 vs. ≤ 27.8)	0.690	0.521–0.914	0.010
VATI (> 49.0 vs. ≤ 49.0)	0.662	0.500–0.877	0.004	0.667	0.497–0.895	0.003
Location (middle/lower vs. neck/upper)	1.601	1.205–2.129	0.001	1.352	1.008–1.812	0.001
Length (≤ 4 vs. > 4)	1.042	0.788–1.378	0.772
Treatment (CRT vs. RT)	0.838	0.619–1.133	0.251
RT dose (≤ 60 vs. > 60)	1.158	0.870–1.542	0.314
TNM stage (III–IV vs. I–II)	1.419	1.225–1.645	< 0.001	1.384	1.193–1.605	< 0.0001
T stage (T3–4 vs. T1–2)	1.269	1.066–1.510	0.007
N stage (N2–3 vs. N0–1)	1.492	1.113–2.001	0.008

HR hazard ratio, CI confidence interval, p values highlighted in bold indicated p < 0.05

ISSN: 1471-230X